Targeting Newly-Identified Brain Protein Brings Hope of New Treatment for Parkinson's Disease

Targeting newly-identified brain protein brings hope of new treatment for Parkinson's disease

Groundbreaking research by the University of Sydney has identified a new brain protein involved in the development of Parkinson's disease and a way to modify it, paving the way for future treatments for the disease.

Phase 2 trial of NEU-411 for LRRK2-driven disease begins dosing

Neuron23 has dosed the first participant in its Phase 2 clinical trial of NEU-411, an investigational treatment for early Parkinson’s disease that targets overactivity in the LRRK2 enzyme. The therapy may benefit individuals with genetic mutations or variations in the LRRK2 gene, which is a key contributor and common genetic driver of Parkinson’s, according to the company. Neuron23 also announced the close of a $96.5-million round of investment …

A newly identified brain protein involved in the development of Parkinson’s disease

Find out how researchers are studying brain protein and its role in Parkinson's disease to develop better therapies.

STUDY: Cinnamon May Slow Progression Of Parkinson’s Disease

by M. Brooks Cinnamon may be the latest addition to the list of recognized “brain” foods. The sweet spice contains a chemical that can help protect the brain and new research shows it may even halt [...]

Targeting newly-identified brain protein brings hope of new treatment

Targeting newly-identified brain protein brings hope of new treatment for Parkinson’s disease Groundbreaking research by the University of Sydney has identified a new brain protein involved in the development of Parkinson’s disease and a way to modify it, paving the way for future treatmen